Development of pre and post-operative models to predict early recurrence of hepatocellular carcinoma after surgical resection

Worldwide, hepatocellular carcinoma (HCC) is the sixth most frequent malignancy and the second most common cause of cancer-related death.[1] There is a wide variety of therapeutic options for HCC patients, depending on tumour burden, liver function and performance status.[2] Potentially curative therapy recommended for those patients with very early/early stage tumour (Barcelona Clinic Liver Cancer [BCLC] 0/A) consists of surgical resection, liver transplantation or local ablation. Due to scarcity of donor organs, surgical resection and ablation are the mainstay of curative treatment options in Asian-Pacific countries, which account for three quarters of all new patients globally.

Source: Journal of Hepatology - September 17, 2018 Category: Gastroenterology Authors: Anthony W.H. Chan, Jianhong Zhong, Sarah Berhane, Hidenori Toyoda, Alessandro Cucchetti, KeQing Shi, Toshifumi Tada, Charing C.N. Chong, Bang-De Xiang, Le-Qun Li, Paul B.S. Lai, Vincenzo Mazzaferro, Marta Garc ía-Fiñana, Masatoshi Kudo, Takashi Kumada, Source Type: research